Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis
Authors
Keywords
-
Journal
INFECTION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-31
DOI
10.1007/s15010-021-01671-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
- (2021) Ahmad Al-Abdouh et al. Contemporary Clinical Trials
- Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19
- (2021) Zhenjian Xu et al. BMC Nephrology
- Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
- (2021) Afra Rezagholizadeh et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials
- (2021) George N. Okoli et al. Infectious Diseases
- Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
- (2020) Miranda Davies et al. DRUG SAFETY
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness
- (2020) Anton Pak et al. Frontiers in Public Health
- Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)
- (2020) François Montastruc et al. Clinical Gastroenterology and Hepatology
- Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care
- (2020) Susan A Olender et al. CLINICAL INFECTIOUS DISEASES
- Remdesivir Use Compared to Supportive Care in Hospitalized Patients with Severe COVID-19: A Single-Center Experience
- (2020) Markos Kalligeros et al. Open Forum Infectious Diseases
- The Rationale for Potential Pharmacotherapy of COVID-19
- (2020) Maha Saber-Ayad et al. Pharmaceuticals
- Remdesivir for Adults With COVID-19
- (2020) Timothy J. Wilt et al. ANNALS OF INTERNAL MEDICINE
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effectiveness of remdesivir for the treatment of hospitalized COVID‐19 persons: A network meta‐analysis
- (2020) Yawen Jiang et al. JOURNAL OF MEDICAL VIROLOGY
- Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis
- (2020) Dhan Bahadur Shrestha et al. LIFE SCIENCES
- Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials
- (2020) Yujiro Yokoyama et al. VIRUS RESEARCH
- Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis
- (2020) Alejandro Piscoya et al. PLoS One
- Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials
- (2020) Yuki Enoki et al. Journal of Global Antimicrobial Resistance
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More